A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs CCX 140 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors ChemoCentryx
- 31 May 2018 Status changed from not yet recruiting to recruiting.
- 23 May 2018 Status changed from planning to not yet recruiting.
- 16 May 2018 New trial record